Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Experimental: [18F]FAPI-74 PET/CT

Patients receive [18F]FAPI-74 intravenously followed by PET/CT 60 minutes (+/-10minutes) later

Drug: [18F]FAPI-74 PET/CT

[18F]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 16, 2023Comments | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine